Empfohlen
Weitere ähnliche Inhalte
Ähnlich wie Al gunduz sales intro to 2008
Ähnlich wie Al gunduz sales intro to 2008 (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
Al gunduz sales intro to 2008
- 1. Sales Meeting – Western Region – January 14 2008 Focus: Taxane Related Products
- 2. Why pursue Taxane based products? “This places screams engineering – engineering is your strong point” - Doug Johnson, Allos:
- 3. Why pursue Taxane based products? Taxane based products require large amounts of engineering • Combination of aqueous & lipid phases • Homogenization • Microfluidization • Possible cytotoxic lyophilization?
- 4. Why pursue Taxane based products? Docetaxel to expire 2010 Vinorelbine – off-patent since 2003
- 5. Lipid-Soluble API Formulation SN-38 NeoPharm, Inc. Enzon Pharmaceuticals, Inc Taxanes RTI, International Cell Therapeutics, Inc. Azaya Therapeutics
- 6. Small to Mid-Pharma with Ongoing Clinical Trials Docetaxel RTI, International Novacea Cell Therapeutics, Inc. Zeneus Pharma Azaya Therapeutics Genta Incorporated MethylGene Poniard Pharmaceuticals Ascenta Therapeutics Seattle Genetics, Inc. Cell Genesys GPC Biotech Titan Pharmaceuticals Proacta, Incorporated Cytogen Corporation Keryx Biopharmaceuticals Tibotec Therapeutics Infinity Pharmaceuticals, Inc. ONYX Pharmaceuticals Cytokinetics, Inc. AmpliMed Corporation Semafore Pharmaceuticals Inc. CPT-11 EMD Serono, Inc. Celgene Corporation Wellstat Therapeutics YM BioSciences Adnexus Dynavax Technologies Corporation ImClone Systems
- 7. Why pursue Taxane based products? Taxane based products require large amounts of engineering • Combination of aqueous & lipid phases • Homogenization • Microfluidization • Possible cytotoxic lyophilization?
- 8. How widespread are Taxane based products How widespread are Taxane based products? Docetaxel Docetaxel- 809 on-going studies Vinorelbine- 160 on-going studies CPT-11- 210 on-going studies SN-38- 13 on-going studies
- 9. Recent News Docetaxel 02 Jan 2008 NEOPHARM, Inc. today announced that it has filed an investigational new drug application with the FDA for a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere(R) (docetaxel), for the treatment of patients with locally advanced or metastatic solid tumor after failure of prior chemotherapy WAUKEGAN, IL, USA | January 2, 2008 | NEOPHARM, Inc. (NASDAQ:NEOL) today announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere(R) (docetaxel), for the treatment of patients with locally advanced or metastatic solid tumor after failure of prior chemotherapy.
- 10. “Promote it and they will come” HCM to Paperazzi Current HCM Client to closest CMO Distance 700 ft Distance 500 ft